- RecruitingPHASE3
Personalized Medicine for Advanced Biliary Cancer Patients
This study looks at whether adding a special "targeted" drug after initial treatment for advanced bile duct cancer works better than continuing standard treatment. It customises treatment based on your tumour's unique features.
For: Biliary Tract NeoplasmsBelgium · France · United Kingdom - Active not recruitingPHASE3
A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma
This study is looking at three new medicines for advanced melanoma, a type of skin cancer. It aims to see if combining these medicines helps people with melanoma that has spread and has a specific gene change called 'BRAF'.
For: MelanomaUnited States · Argentina · Austria - Ongoing, recruitingTherapeutic exploratory (Phase II)
C4221023 - A PHASE 2, RANDOMIZED, OPEN-LABEL STUDY OF ENCORAFENIB AND BINIMETINIB PLUS PEMBROLIZUMAB VERSUS NIVOLUMAB AND IPILIMUMAB IN PARTICIPANTS WITH BRAF V600E/K MUTATION-POSITIVE MELANOMA WHO PROGRESSED DURING OR AFTER PRIOR TREATMENT WITH ANTI−PD-1 THERAPY
This study is looking at new drug combinations for people with a certain type of advanced melanoma that has not responded to previous treatment. It compares two groups of medicines to see which works better at shrinking the cancer.
For: Metastatic or unresectable locally advanced BRAF V600E/K mutation positive melanomaSpain · Germany · Slovakia - Ongoing, recruitingTherapeutic use (Phase IV)
Surgical or radiotherapeutic intervention concerning large singular stable to progressive metastases in patients with BRAFV600-mutated melanoma receiving treatment with Encorafenib + Binimetinib
This study looks at how well different treatments like surgery or radiotherapy work for people with a specific type of advanced melanoma. They are already taking two medicines, Encorafenib and Binimetinib, and researchers want to see if adding these other treatments helps them live longer without their cancer growing.
For: Unresectable or metastatic melanoma with a BRAF V600 mutation (inoperable stage III or metastatic stage IV)Germany